Combined Immune Checkpoint Blockade and Helixor(®) Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW).

Thronicke A, Grabowski P, Roos J, Wüstefeld H, Grah C, Johnson S, Schad F

DOI: 10.3390/ijms26083669
Published: 2025 Apr 12
Container: International journal of molecular sciences
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/ijms26083669,
  title = {Combined Immune Checkpoint Blockade and Helixor(®) Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW).},
  author = {Thronicke A and Grabowski P and Roos J and Wüstefeld H and Grah C and Johnson S and Schad F},
  year = {2025},
  journal = {International journal of molecular sciences},
  doi = {10.3390/ijms26083669},
  url = {https://doi.org/10.3390/ijms26083669}
}

RIS

TY  - JOUR
TI  - Combined Immune Checkpoint Blockade and Helixor(®) Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW).
AU  - Thronicke A
AU  - Grabowski P
AU  - Roos J
AU  - Wüstefeld H
AU  - Grah C
AU  - Johnson S
AU  - Schad F
PY  - 2025
JO  - International journal of molecular sciences
DO  - 10.3390/ijms26083669
UR  - https://doi.org/10.3390/ijms26083669
ER  -

APA

A, T., P, G., J, R., H, W., C, G., S, J., & F, S. (2025). Combined Immune Checkpoint Blockade and Helixor(®) Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW).. International journal of molecular sciences. https://doi.org/10.3390/ijms26083669

Source records

pubmed · retrieved 2026-09-26T13:47:08.828Z